Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ernesto Moreno

Showing results (1-10 of 59) with videos related to

Pageof 6
Sort By:
Journal of Molecular Graphics & Modelling|November 26, 2008
Do rotamer libraries reproduce the side-chain conformations of peptidic ligands from the PDB?Amaury Pupo, Ernesto Moreno
Proteins|March 1, 2002
Geometric and chemical patterns of interaction in protein--ligand complexes and their application in dockingErnesto Moreno, Kalet León
Chinese Clinical Oncology|April 6, 2015
EGFR-targeting therapy as an evolving concept: learning from nimotuzumab clinical developmentRolando Perez, Ernesto Moreno
IEEE/ACM Transactions on Computational Biology and Bioinformatics|October 31, 2009
Evaluation of geometric complementarity between molecular surfaces using compactly supported radial basis functionsLuis A Diago, Ernesto Moreno
Cancers|November 12, 2013
EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab's Clinical EffectsRolando Perez, Ernesto Moreno, Greta Garrido, et al.
Frontiers in Pharmacology|May 3, 2013
A view on EGFR-targeted therapies from the oncogene-addiction perspectiveRolando Perez, Tania Crombet, Joel de Leon, et al.
BMC Bioinformatics|August 28, 2007
Setting up a large set of protein-ligand PDB complexes for the development and validation of knowledge-based docking algorithmsLuis A Diago, Persy Morell, Longendri Aguilera, et al.
Current Drug Targets|February 5, 2016
Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and ItolizumabPatricia Hernández, Ernesto Moreno, Lazaro E Aira, et al.
ACS Chemical Biology|November 10, 2012
Engineering the binding site of an antibody against N-glycolyl GM3: from functional mapping to novel anti-ganglioside specificitiesGertrudis Rojas, Amaury Pupo, Silvia Gómez, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 16, 2011
Nimotuzumab and cetuximab block ligand-independent EGF receptor signaling efficiently at different concentrationsChristian Berger, Ute Krengel, Espen Stang, et al.
Pageof 6

Showing results (1-10 of 59) with videos related to

Sort By:
Pageof 6
Journal of Molecular Graphics & Modelling|November 26, 2008
Do rotamer libraries reproduce the side-chain conformations of peptidic ligands from the PDB?Amaury Pupo, Ernesto Moreno
Proteins|March 1, 2002
Geometric and chemical patterns of interaction in protein--ligand complexes and their application in dockingErnesto Moreno, Kalet León
Chinese Clinical Oncology|April 6, 2015
EGFR-targeting therapy as an evolving concept: learning from nimotuzumab clinical developmentRolando Perez, Ernesto Moreno
IEEE/ACM Transactions on Computational Biology and Bioinformatics|October 31, 2009
Evaluation of geometric complementarity between molecular surfaces using compactly supported radial basis functionsLuis A Diago, Ernesto Moreno
Cancers|November 12, 2013
EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab's Clinical EffectsRolando Perez, Ernesto Moreno, Greta Garrido, et al.
Frontiers in Pharmacology|May 3, 2013
A view on EGFR-targeted therapies from the oncogene-addiction perspectiveRolando Perez, Tania Crombet, Joel de Leon, et al.
BMC Bioinformatics|August 28, 2007
Setting up a large set of protein-ligand PDB complexes for the development and validation of knowledge-based docking algorithmsLuis A Diago, Persy Morell, Longendri Aguilera, et al.
Current Drug Targets|February 5, 2016
Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and ItolizumabPatricia Hernández, Ernesto Moreno, Lazaro E Aira, et al.
ACS Chemical Biology|November 10, 2012
Engineering the binding site of an antibody against N-glycolyl GM3: from functional mapping to novel anti-ganglioside specificitiesGertrudis Rojas, Amaury Pupo, Silvia Gómez, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 16, 2011
Nimotuzumab and cetuximab block ligand-independent EGF receptor signaling efficiently at different concentrationsChristian Berger, Ute Krengel, Espen Stang, et al.
Pageof 6